Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

NCT01854034 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01854034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01854034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
March 31, 2017
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer